{
  "meta": {
    "title": "Sex_Hormones",
    "url": "https://brainandscalpel.vercel.app/sex-hormones-5e8ef636.html",
    "scrapedAt": "2025-11-29T18:33:55.195Z"
  },
  "questions": [
    {
      "id": 3965,
      "choices": [
        {
          "id": 15839,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
        },
        {
          "id": 15840,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dapagliflozin</span></span></span></p>"
        },
        {
          "id": 15841,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
        },
        {
          "id": 15842,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old female with a history of type 2 diabetes mellitus presents to the clinic with complaints of recurrent urinary tract infections (UTIs) over the past few months. She reports symptoms of urgency, frequency, and dysuria. Her diabetes has been managed with an antidiabetic medication added to her regimen about 6 months ago, around the time the UTIs started becoming more frequent. Her medical history is otherwise unremarkable, and she is not on any other new medications. Which of the following drugs in her treatment regimen is most likely implicated in causing this adverse effect?</span></span></span></p>",
      "unique_key": "Q7541641",
      "question_audio": null,
      "question_video": null,
      "map_id": 36147,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Dapagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dapagliflozin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a<strong> Sodium-glucose cotransporter 2 (SGLT2) inhibitor</strong> used in the management of<strong> type 2 diabetes mellitus. </strong>SGLT2 <strong>inhibitors</strong> work by<strong> preventing glucose reabsorption in the kidneys,</strong> leading to the <strong>excretion of glucose in the urine</strong>. This mechanism can <strong>increase the risk of urinary tract infections (UTIs) </strong>due to the<strong> higher glucose</strong> content in the<strong> urine,</strong> which can provide a<strong> medium</strong> <strong>for bacterial growth</strong>. The temporal association between the<strong> start of the medication and the onset of recurrent UTIs</strong> in this patient suggests that <strong>dapagliflozin </strong>is the<strong> most</strong> probable <strong>antidiabetic drug </strong>implicated in causing this<strong> adverse effect.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Sitagliptin&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">and <strong>C. Linagliptin</strong>: Both are <strong>Dipeptidyl peptidase-4 (DPP-4) inhibitors. </strong>They work by <strong>increasing incretin levels,</strong> which<strong> inhibit glucagon release and increase insulin secretion</strong>. DPP-4 inhibitors are <strong>not </strong>commonly associated with an <strong>increased risk</strong> <strong>of UTIs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pramlintide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: An<strong> amylin analogue </strong>used in addition to <strong>insulin therapy in type 1 and type 2 diabetes</strong> to improve <strong>glycemic</strong> control.<strong> Pramlintide </strong>is <strong>not </strong>associated with an<strong> increased risk of UTIs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dapagliflozin is an SGLT2 inhibitor </strong>that can<strong> increase the risk of urinary tract infections</strong> due to <strong>glucosuria,</strong> which can encourage <strong>bacterial growth </strong>in the urinary tract. <strong>Important points about SGLT2 Inhibitors are -</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These<strong> reduce reabsorption of filtered glucose</strong> and <strong>lowers the renal threshold for glucose</strong>, and thereby <strong>increases urinary</strong> <strong>glucose excretion.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These are <strong>NOT </strong>recommended for patients with <strong>type 1 diabetes mellitus</strong> or for the treatment of <strong>diabetic ketoacidosis.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These should<strong> NOT</strong> be initiated in patients with an&nbsp;<strong>eGFR less than 60 mL/min/1 .73 m<sup>2.</sup></strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Adverse Effects:</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Increases </strong>the risk of <strong>genital mycotic infections.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Urinary tract infections.</strong></span></span></span></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypotension.</span></span></span></strong></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">I<strong>mpairment in Renal Function.</strong></span></span></span></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</span></span></span></strong></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>",
      "correct_choice_id": 15840,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3632,
      "choices": [
        {
          "id": 14507,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corticosteroids</span></span></span></p>"
        },
        {
          "id": 14508,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">DDAVP</span></span></span></p>"
        },
        {
          "id": 14509,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin K</span></span></span></p>"
        },
        {
          "id": 14510,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tranexamic acid</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old male presents to the clinic with a history of mild hemophilia A. He reports experiencing prolonged bleeding after minor injuries and is seeking options for management. Which of the following drug can be used in the treatment of mild hemophilia?&nbsp; </span></span></span></p>",
      "unique_key": "Q2318300",
      "question_audio": null,
      "question_video": null,
      "map_id": 36140,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. DDAVP</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>DDAVP</strong> is other name of <strong>desmopressin</strong>. </span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is the <strong>drug of choice </strong>for the treatment of <strong>mild hemophilia A.</strong> Desmopressin is a <strong>synthetic</strong> <strong>analog </strong>of the <strong>natural antidiuretic hormone vasopressin. </strong>It works by stimulating <strong>V2 receptors</strong> that result in the <strong>release of von</strong> <strong>Willebrand factor and factor VIII from endothelial cells</strong>. This<strong> increase in factor VIII levels </strong>can<strong> temporarily correct </strong>the <strong>clotting defect</strong> in patients with <strong>mild hemophilia A,</strong> thereby <strong>reducing the risk of bleeding </strong>during <strong>surgeries or after injuries</strong>. <strong>DDAVP</strong> can be administered <strong>intravenously, subcutaneously, or as a nasal spray, </strong>making it a<strong> versatile</strong> and effective option for<strong> managing mild</strong> <strong>hemophilia A.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin K</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is essential for the <strong>synthesis </strong>of certain <strong>clotting factors (II, VII, IX, and X) </strong>but is<strong> not </strong>effective in <strong>treating hemophilia, </strong>which is caused by a<strong> deficiency or dysfunction of factor VIII (in hemophilia A) or factor IX (in hemophilia B),</strong> <strong>not by a vitamin K deficiency.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Corticosteroids</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are <strong>not used</strong> in the treatment of <strong>hemophilia. </strong>They are primarily used to<strong> treat inflammation and</strong> <strong>autoimmune conditions</strong> and have<strong> no role </strong>in <strong>increasing clotting factors in hemophilia patients.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tranexamic acid</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>antifibrinolytic agent</strong> that prevents the <strong>breakdown of blood clots. </strong>While it can be useful in managing <strong>bleeding in hemophilia patients</strong>, particularly in <strong>mucosal bleeding or during dental procedures,</strong> it <strong>does not </strong>address the underlying<strong> clotting factor deficiency</strong> and is typically used as an <strong>adjunct to factor replacement therapy</strong> rather than as a <strong>primary</strong> treatment.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>aim </strong>is to understand the <strong>treatment modalities </strong>available for managing <strong>mild hemophilia A,</strong> with a focus on the use of <strong>DDAVP</strong> <strong>(Desmopressin)</strong> as an effective option for <strong>increasing the levels of factor VIII,</strong> thereby<strong> temporarily </strong>correcting the <strong>clotting defect</strong>. </span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can result in <strong>release of factor VIII and vWF from the endothelium.</strong> </span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> </span></span></span></span></span></span></p>",
      "correct_choice_id": 14508,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3721,
      "choices": [
        {
          "id": 14863,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine</span></span></span></p>"
        },
        {
          "id": 14864,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methysergide</span></span></span></p>"
        },
        {
          "id": 14865,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine</span></span></span></p>"
        },
        {
          "id": 14866,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ondansetron</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is used in the treatment of hyperprolactinemia? </span></span></span></p>",
      "unique_key": "Q9732194",
      "question_audio": null,
      "question_video": null,
      "map_id": 36139,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Bromocriptine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>dopamine agonist </strong>that is used in the treatment of <strong>hyperprolactinemia</strong>. Hyperprolactinemia is a condition characterized by <strong>elevated levels of prolactin </strong>in the blood, which can cause various symptoms, including <strong>amenorrhea, galactorrhea,</strong> <strong>infertility, and hypogonadism</strong>. Bromocriptine works by<strong> activating dopamine D2 receptors</strong>, which <strong>inhibits the secretion of prolactin</strong> from the<strong> pituitary gland.</strong> It is an effective treatment for <strong>lowering prolactin levels </strong>and <strong>alleviating the symptoms </strong>associated with <strong>hyperprolactinemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Cimetidine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Cimetidine is a <strong>histamine H2 receptor antagonist </strong>used primarily to treat <strong>peptic ulcer disease and</strong> g<strong>astroesophageal reflux disease (GERD)</strong>. It is <strong>not </strong>used in the treatment of <strong>hyperprolactinemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Methysergide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Methysergide</strong> is a medication used to <strong>prevent migraine headache.</strong> It is not used for the treatment of hyperprolactinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ondansetron</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Ondansetron is a <strong>serotonin 5-HT3 receptor antagonist </strong>used primarily to <strong>prevent nausea and vomiting</strong> associated with <strong>chemotherapy, radiation therapy, and surgery. </strong>It is <strong>not </strong>used in the treatment of <strong>hyperprolactinemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uses of Dopamine Agonists</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture7.jpg\" style=\"height:396px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 14865,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3954,
      "choices": [
        {
          "id": 15795,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glibenclamide&mdash;Na K ATPase blocker</span></span></span></p>"
        },
        {
          "id": 15796,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Biguanides&mdash;AMP kinase activation</span></span></span></p>"
        },
        {
          "id": 15797,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin&mdash;SGLT2 inhibitor</span></span></span></p>"
        },
        {
          "id": 15798,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Voglibose&mdash;DPP4 inhibitor</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following pairs of antidiabetic drug and its mechanism of action is correct?</span></span></span></p>",
      "unique_key": "Q9391431",
      "question_audio": null,
      "question_video": null,
      "map_id": 36142,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Biguanides&mdash;AMP kinase activation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Biguanides, specifically metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, the most commonly used drug in this class, work by <strong>activating AMP-activated protein kinase (AMPK)</strong>. This activation leads to a<strong> decrease in hepatic glucose production (gluconeogenesis) </strong>and an <strong>increase in insulin sensitivity,</strong> which enhances <strong>peripheral glucose uptake. </strong>This mechanism contributes to the<strong> lowering of blood glucose levels without </strong>stimulating <strong>insulin secretion</strong>, making it a foundational treatment for<strong> type 2 diabetes mellitus.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Glibenclamide&mdash;Na K ATPase blocker</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This statement is<strong> incorrect. Glibenclamide</strong> (also known as<strong> glyburide </strong>in some regions) is a <strong>sulfonylurea</strong>, which acts as a <strong>K_ATP channel blocker</strong> on <strong>pancreatic beta cells,</strong> thereby <strong>stimulating insulin secretion</strong>. It <strong>does not block Na K ATPase.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Vildagliptin&mdash;SGLT2 inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This statement is <strong>incorrect.</strong> Vildagliptin is a <strong>DPP-4 inhibitor</strong>, not an SGLT2 inhibitor. It works by <strong>preventing the breakdown of incretin hormones</strong>, which <strong>increases insulin release and decreases glucagon levels </strong>in a glucose-dependent manner.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Voglibose&mdash;DPP4 inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This statement is<strong> incorrect</strong>. Voglibose is an <strong>alpha-glucosidase inhibitor</strong>, not a DPP-4 inhibitor. It works by <strong>delaying the digestion of carbohydrates</strong>, thereby <strong>blunting postprandial blood glucose spikes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Biguanides </strong>like<strong> metformin activate AMPK, l</strong>eading to <strong>decreased hepatic glucose production and increased insulin sensitivity without directly stimulating insulin secretion</strong>. This<strong> mechanism</strong> is fundamental in the management of<strong> type 2 diabetes, </strong>making it a cornerstone of therapy.</span></span></p>",
      "correct_choice_id": 15796,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3958,
      "choices": [
        {
          "id": 15811,
          "text": "<p>​​​​​​<span style=\"font-size:12pt;\">Pramlintide</span></p>"
        },
        {
          "id": 15812,
          "text": "<p><span style=\"font-size:12pt;\">Canagliflozin</span></p>"
        },
        {
          "id": 15813,
          "text": "<p><span style=\"font-size:12pt;\">Exenatide</span></p>"
        },
        {
          "id": 15814,
          "text": "<p><span style=\"font-size:12pt;\">Vildagliptin</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Drug Z shown in figure is likely to be?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture17.jpg\" alt=\"\" width=\"600\" height=\"358\"></span></p>",
      "unique_key": "Q1281177",
      "question_audio": null,
      "question_video": null,
      "map_id": 36143,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. Canagliflozin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The diagram </span><span style=\"font-size:12.0pt;\">illustrates normal physiology of urine formation, </span><span style=\"font-size:12pt;\"><strong>renal glucose reabsorption process, highlighting SGLT2 and SGLT1 co-transporters. </strong></span><span style=\"font-size:12.0pt;\">Normally SGLT 2 cotransporter is present in proximal tubule, so no glucose is seen in urine.</span><span style=\"font-size:12pt;\"><strong> Canagliflozin</strong> is a <strong>Sodium-glucose co-transporter-2 (SGLT-2) inhibitor.</strong> It works by<strong> inhibiting the SGLT2 transporter,</strong> which is responsible for <strong>90% of</strong> <strong>glucose reabsorption in the kidney, </strong>as shown by the marked location in the<strong> proximal tubule</strong> in the figure. By <strong>inhibiting</strong> this <strong>transporter, Canagliflozin </strong>causes<strong> increased excretion of glucose in the urine (glucosuria), </strong>thus <strong>lowering blood glucose levels</strong> in patients with <strong>type 2 diabetes.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p><br><span style=\"font-size:12pt;\"><strong>Option A.</strong> <strong>Pramlintide</strong> is <strong>incorrect</strong> because it is an<strong> amylin analogue</strong>, <strong>not an SGLT2 inhibitor.</strong> It is used in the treatment of <strong>type 1 and</strong> <strong>type 2 diabetes mellitus </strong>to complement insulin therapy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong> <strong>Exenatide</strong> is<strong> incorrect </strong>because it is a<strong> GLP-1 (glucagon-like peptide-1) analogue</strong>, which stimulates <strong>insulin release</strong> and is not involved in the renal reabsorption of glucose.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong> <strong>Vildagliptin</strong> is<strong> incorrect </strong>because it is a<strong> DPP-4 (Dipeptidyl peptidase-4) inhibitor </strong>that prolongs the action of <strong>endogenous</strong> <strong>GLP-1,</strong> thereby <strong>increasing insulin secretion,</strong> but <strong>does not</strong> directly cause<strong> glucosuria as SGLT2 inhibitors do.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Sodium glucose co-transporter-2 inhibitors (SGLT-2 inhibitors):</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Glucose </strong>is<strong> freely filtered </strong>by the <strong>renal glomeruli </strong>and is <strong>reabsorbed in the proximal tubules</strong> by the action of <strong>sodium-glucose transporters (SGLTs).</strong></span></li><li><span style=\"font-size:12pt;\">Sodium-glucose transporter 2 (SGLT2) accounts for <strong>90% of glucose reabsorption</strong>, and its <strong>inhibition causes glycosuria and</strong> <strong>lowers glucose levels in patients with type 2 diabetes.</strong></span></li><li><span style=\"font-size:12pt;\">SGLT2 inhibitors <strong>lower glucose levels</strong> by changing the <strong>renal threshold</strong> and not by insulin action.</span></li><li><span style=\"font-size:12pt;\">The <strong>SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin</strong>, all oral medications, are approved for clinical use.</span></li><li><span style=\"font-size:12pt;\"><strong>Side effects</strong> of SGLT2 <strong>inhibitors include ketoacidosis, urosepsis, Fournier's gangrene, increased incidence of UTI and genital infections.</strong></span></li></ul>",
      "correct_choice_id": 15812,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3960,
      "choices": [
        {
          "id": 15819,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Monophasic combined OCPs</span></span></span></p>"
        },
        {
          "id": 15820,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Biphasic combined OCPs</span></span></span></p>"
        },
        {
          "id": 15821,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triphasic combined OCPs</span></span></span></p>"
        },
        {
          "id": 15822,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Emergency pills</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The oral contraceptives shown in the figure are.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture19.jpg\" style=\"height:194px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q6639365",
      "question_audio": null,
      "question_video": null,
      "map_id": 36144,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Monophasic combined OCPs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Figure shows <strong>monophasic oral contraceptive pills. 28 tablets </strong>with<strong> 21 one colored (</strong>with same hormone content of <strong>Estrogen and Progesterone)</strong> and <strong>7 different coloreds</strong> (contains only <strong>iron without Estrogen and Progesterone</strong>). </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note: Please do not mark the answer as biphasic pills by seeing two colors in the drug strip.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B. Biphasic pills will have three colors.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The <strong>first 10 tablets </strong>with <strong>less content of E+P, </strong>the next <strong>11 tablets of different color</strong> containing <strong>higher amounts of hormones </strong>and last<strong> 7 tablets of different color</strong> that contain only <strong>iron.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. Triphasic pills will have four colors.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> First 6 tablets, 6-10 tablets, 11-21 tablets and last 7 tablets </strong>of <strong>different color.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp; <strong>Emergency pills</strong> are <strong>incorrect</strong> because<strong> emergency contraception</strong> is<strong> not</strong> presented in a<strong> 28-day </strong>format but rather as a<strong> one-time dose </strong>or a <strong>short series of pills</strong> intended for <strong>immediate use after unprotected sex.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<br />\r\n<strong>Monophasic combined OCPs</strong> consist of <strong>21 active pills</strong> with a consistent dose of <strong>estrogen and progesterone</strong>, followed by <strong>7 non-hormonal (iron) pills,</strong> and are represented in a pack with <strong>two colors&mdash;21 of one color</strong> and <strong>7 of another, </strong>not to be confused with <strong>biphasic or triphasic pills </strong>which have<strong> varying hormone dosages and more color variation.</strong></span></span></span></p>",
      "correct_choice_id": 15819,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4249,
      "choices": [
        {
          "id": 16973,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Previous hysterectomy</span></span></span></p>"
        },
        {
          "id": 16974,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrent vaginitis</span></span></span></p>"
        },
        {
          "id": 16975,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Strong family history of breast cancer</span></span></span></p>"
        },
        {
          "id": 16976,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Troublesome hot flushes</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">52-year-old postmenopausal patient has evidence of low bone mineral density. She and her physician are considering therapy with raloxifene or a combination of conjugated estrogens and medroxyprogesterone acetate. Which of the following patient characteristics is most likely to lead them to select raloxifene? </span></span></span></p>",
      "unique_key": "Q6466167",
      "question_audio": null,
      "question_video": null,
      "map_id": 36145,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Strong family history of breast cancer</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Raloxifene</strong> is a<strong> selective estrogen receptor modulator (SERM) </strong>that has<strong> estrogenic effects on bone</strong> and <strong>lipid metabolism </strong>but <strong>acts as</strong> an<strong> estrogen antagonist on breast and endometrial tissues</strong>. Given its <strong>antagonistic effects on breast tissue,</strong> raloxifene can decrease the risk of <strong>breast cancer</strong>, which makes it a particularly <strong>suitable choice for a patient with a strong family history of breast cancer. </strong>This <strong>contrasts </strong>with<strong> hormone replacement therapy (HRT) </strong>using a combination of <strong>estrogen and progesterone,</strong> which has been associated with an<strong> increased risk of breast cancer.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Previous hysterectomy:</strong> Previous hysterectomy is a<strong> better option </strong>fo<strong>r those drugs</strong> which<strong> increase risk of endometrial</strong> <strong>carcinoma,</strong> as there is <strong>no endometrium, </strong>so<strong> no risk.</strong> As <strong>raloxifene does not increase the risk</strong> (rather it<strong> decreases the risk</strong>) of <strong>endometrial carcinoma, </strong>this characteristic<strong> would not </strong>influence the <strong>choice towards raloxifene. </strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Recurrent vaginitis:</strong> <strong>Patients suffering</strong> from <strong>recurrent vaginitis </strong>might <strong>benefit more from estrogen therapy, </strong>which can help maintain <strong>vaginal health and pH balance</strong>, rather than raloxifene.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Troublesome hot flushes:</strong> Raloxifene is <strong>not effective for the treatment of hot flushes</strong> and might actually<strong> exacerbate them.</strong> In this case, <strong>HRT would be more appropriate</strong> to <strong>alleviate menopausal symptoms</strong> such as <strong>hot flushes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hormone replacement therapy (Combination of estrogen and progesterone) </strong>increases the risk of <strong>breast cancer </strong>whereas <strong>raloxifene</strong> has<strong> protective effective on breast cancer.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Actions of Raloxifene:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a <strong>selective estrogen receptor modulator.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It acts like an <strong>estrogen agonist in bone</strong> and<strong> decreases bone resorption</strong>. Thus, it is used for treatment of <strong>osteoporosis.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> increases HDL/LDL cholesterol ratio</strong> and thus has a favorable effect on<strong> lipid profile.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> acts as ER antagonist </strong>on<strong> breast and endometrial tissue </strong>and thus can<strong> decrease the risk of breast cancer</strong> as well as <strong>endometrial cancer.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> increases </strong>the formation of<strong> clotting factors</strong> and thus the risk of<strong> thromboembolism is increased</strong> with the<strong> use of</strong> <strong>raloxifene</strong>.</span></span></span></span></span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 16975,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3642,
      "choices": [
        {
          "id": 14547,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quick relief of symptoms</span></span></span></p>"
        },
        {
          "id": 14548,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To increase the metabolism of thyroxine</span></span></span></p>"
        },
        {
          "id": 14549,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To blockade the thyroxine receptors</span></span></span></p>"
        },
        {
          "id": 14550,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To decrease the synthesis of thyroxine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroid storm is medical emergency in which there is excessive secretion of thyroid hormones. Beta blockers like propranolol are commonly used in a patient of thyroid storm. What is the most important role of beta blockers in these patients?</span></span></span>​​​​​​</p>",
      "unique_key": "Q8294768",
      "question_audio": null,
      "question_video": null,
      "map_id": 36146,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Quick relief of symptoms </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroid storm (Thyrotoxic Crisis)</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is<strong> an emergency</strong> due to <strong>decompensated hyperthyroidism.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment includes:</span></span></span></li>\r\n</ul>\r\n\r\n<ol>\r\n\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-selective &beta;-blocker </span></span></span></strong>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is the<strong> mos</strong>t valuable measure in <strong>thyroid storm. </strong>In thyroid storm most of the symptoms are <strong>because of</strong> <strong>adrenergic overactivity. </strong>This occurs due to<strong> increased tissue sensitivity to catecholamines </strong>(resulting from upregulation of &beta;-receptors) in <strong>hyperthyroidism. </strong>So, quick relief can be obtained by <strong>blocking &beta;-receptors.</strong> <strong>Propranolol is a lifesaving drug in thyroid storm. </strong>It <strong>not only reverses the symptom</strong>s but also <strong>decrease the</strong> <strong>peripheral conversion of T4 to T3.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Calcium channel blocker</strong>s like <strong>diltiazem</strong> may be added if <strong>tachycardia</strong> is <strong>not </strong>controlled by <strong>propranolol alone.</strong></span></span></span></li>\r\n\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propylthiouracil</span></span></span></strong>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is the <strong>antithyroid drug of choice for thyroid storm</strong> because it <strong>reduces hormone synthesis</strong> as well as <strong>peripheral conversion of T4 to T3.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note: <strong>Propylthiouraci</strong>l is the<strong> DOC </strong>amongst<strong> antithyroid drugs</strong>, but the<strong> DOC for thyroid storm is &beta;-blockers.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corticosteroid (Hydrocortisone) </span></span></span></strong>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> inhibits </strong>both <strong>release of thyroid hormone from the gland and peripheral conversion of T4 to T3.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. To increase the metabolism of thyroxine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> because<strong> beta blockers do not increase the metabolism of thyroxine but reduce the conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. To blockade the thyroxine receptors:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because <strong>beta blockers do not</strong> affect <strong>thyroxine receptors;</strong> they <strong>block &beta;-adrenergic receptors.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. To decrease the synthesis of thyroxine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as beta blockers<strong> do not</strong> directly <strong>decrease the synthesis of thyroid</strong> <strong>hormones</strong>; this effect is<strong> mediated by drugs</strong> like <strong>propylthiouracil.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Additional Treatment Insights:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Calcium channel blockers</strong> like<strong> diltiazem </strong>may be used if<strong> tachycardia persists despite beta-blocker therapy</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Propylthiouracil </strong>is the preferred<strong> antithyroid drug </strong>as it <strong>reduces hormone synthesis</strong> and<strong> peripheral conversion of T4 to</strong> <strong>T3.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Corticosteroids</strong> like <strong>hydrocortisone</strong> are administered to<strong> inhibit both the release of thyroid hormone from the gland and</strong> <strong>the peripheral conversion of T4 to T3.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>thyroid storm, beta blockers</strong> such as<strong> propranolol</strong> are essential for quickly <strong>alleviating symptoms</strong> through<strong> &beta;-receptor blockade </strong>and<strong> reducing the peripheral conversion of T4 to T3</strong>, thereby <strong>mitigating </strong>the effects of <strong>excess thyroid hormones.</strong></span></span></span></span></span></p>",
      "correct_choice_id": 14547,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3953,
      "choices": [
        {
          "id": 15791,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta galactosidase inhibitor</span></span></span></p>"
        },
        {
          "id": 15792,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta lactase inhibitor</span></span></span></p>"
        },
        {
          "id": 15793,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha glucosidase inhibitor</span></span></span></p>"
        },
        {
          "id": 15794,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta glucosidase inhibitor</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism of action of Voglibose is?</span></span></span></p>",
      "unique_key": "Q1440014",
      "question_audio": null,
      "question_video": null,
      "map_id": 36141,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Alpha glucosidase inhibitor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Voglibose</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> acts as an <strong>alpha-glucosidase inhibitor</strong>. This class of medications works by <strong>inhibiting alpha-glucosidase enzymes</strong> in the <strong>small intestine </strong>responsible for<strong> breaking down carbohydrates into glucose.</strong> By inhibiting these enzymes, v<strong>oglibose slows down the</strong> <strong>digestion and absorption of carbohydrates,</strong> leading to a <strong>more gradual rise in blood glucose levels post-meal</strong>. This mechanism makes <strong>alpha-glucosidase inhibitors effective</strong> in managing<strong> postprandial hyperglycemia </strong>in people with<strong> type 2 diabetes mellitus.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Beta galactosidase inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: There is<strong> no therapeutic class</strong> specifically targeting<strong> beta galactosidase for diabetes</strong> management. Beta galactosidase is involved in the<strong> metabolism of lactose into glucose and galactose.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Beta lactase inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The term &quot;beta lactase&quot; is <strong>incorrect as lactase (not &quot;beta lactase&quot;) i</strong>s the enzyme that b<strong>reaks down</strong> <strong>lactose into glucose and galactose,</strong> and there are <strong>no diabetes medications targeting this enzyme.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Beta glucosidase inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Beta glucosidase plays a role in <strong>carbohydrate digestion</strong>, but <strong>inhibiting this enzyme</strong> is <strong>not a</strong> mechanism utilized by<strong> voglibose or other antidiabetic drugs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></span></strong></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\">&nbsp;<br />\r\n<span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Voglibose</strong> is an <strong>alpha-glucosidase inhibitor </strong>used to manage <strong>postprandial blood glucose levels in patients with type 2 diabetes</strong>. Its primary action is to <strong>slow carbohydrate digestion and absorption, </strong>which helps in<strong> controlling spikes in blood sugar levels after meals.</strong></span></span></span></p>",
      "correct_choice_id": 15793,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}